Category: PLC Systems Inc.Syndicate content

PLC Systems reports revenue surge in 3rd quarter

November 15, 2013 by Chris Walker

PLC Systems reported a revenue surge, which has allowed the company to reduce its losses significantly.

PLC Systems reports revenue surge in 3rd quarter

PLC Systems (OTC:PLCSF) is cutting down on its losses, thanks in part to strong revenues during the 3rd quarter.

PLC Systems posted losses of $609,000, or -1¢ per share, on sales of $348,000 for the 3 months ended Sept. 30, narrowing losses by 81% and boosting sales 64.2% over the same period last year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

PLC Systems lands Japanese OK for RenalGuard trial

October 18, 2013 by Chris Walker

The Japanese Ministry of Health, Labor & Welfare approves a clinical trial of PLC Systems' RenalGuard device.

PLC Systems lands Japanese OK for RenalGuard trial

PLC Systems (OTC:PLCSF) won approval from the Japanese Ministry of Health, Labor & Welfare for a clinical trial of its RenalGuard device.

PLC Systems raises $1.8M through common stock

September 19, 2013 by Arezu Sarvestani

Massachusetts-based PLC Systems touts a $1.75 million raise through sales of common stock and 5-year warrants.

PLC Systems raises $1.8M through common stock

Medical device maker PLC Systems (PINK:PLCSF) touted a new $1.75 million raise, which the company plans to use to fund its ongoing U.S. pivotal trial for the RenalGuard system.

TAVI: PLC Systems launches RenalGuard trial

September 16, 2013 by Sony Salzman

PLC Systems treats the 1st patient with its RenalGuard in a trial to evaluate the device in patients with acute kidney failure undergoing heart valve replacement procedures.

TAVI: PLC Systems launches RenalGuard trial

PLC Systems (PINK:PLCSF) said its RenalGuard device was used in a new clinical trial evaluating the device in treating patients with acute kidney failure undergoing transcatheter aortic valve implantation.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA approves 1st Type 2 diabetes drug | Wall Street Beat

April 1, 2013 by Brad Perriello

The FDA approves Johnson & Johnson's 1st-of-a-kind Invokana diabetes drug, designed to flush unabsorbed sugar from the bloodstream.

MassDevice.com Wall Street Beat

The FDA approved a 1st-of-its-kind treatment for Type 2 diabetes, Johnson & Johnson's (NYSE:JNJ) Invokana, with the federal watchdog agency citing it as a pioneer in a new class of diabetes drug.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

PLC Systems touts $1M now, $1M later for U.S. RenalGuard trials | Funding Roundup

July 2, 2012 by MassDevice staff

PLC Systems lands $1 million in funding and plans a pair of $500,000 rounds to support U.S. clinical trials of its RenalGuard system.

Funding Roundup

 PLC Systems touts $1M now, $1M later for RenalGuard trials

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp